2-(3,7,11-trimethyldodeca-2,6,10-trienyl)malonic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(3,7,11-trimethyldodeca-2,6,10-trienyl)malonic acid
• 英文别名: 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]propanedioic acid
• 化学式: C₁₈H₂₈O₄
• 分子量: 308.418
• InChiKey: RZLLNARKHJHJMW-YFVJMOTDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3,7,11-trimethyldodeca-2,6,10-trienyl)malonic acid 在 吡啶 作用下， 反应 5.0h， 生成 4,8,12-十四碳三烯酸,5,9,13-三甲基-,甲基酯,(4E,8E)-
  参考文献：
  名称：

  Superacid cyclization of esters of some bishomoisoprenoid acids

  摘要：

  DOI：

  10.1007/bf00630430
• 作为产物：
  描述：

  反,反-法呢基溴 在 氢氧化钾 、 苄基三乙基氯化铵 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 10.0h， 生成 2-(3,7,11-trimethyldodeca-2,6,10-trienyl)malonic acid
  参考文献：
  名称：

  Superacid cyclization of esters of some bishomoisoprenoid acids

  摘要：

  DOI：

  10.1007/bf00630430

文献信息

• Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: Synthesis and biological evaluation of new farnesylpyrophosphate analogues
  作者：Stéphanie Duez、Laëtitia Coudray、Elisabeth Mouray、Philippe Grellier、Joëlle Dubois

  DOI：10.1016/j.bmc.2009.12.017

  日期：2010.1

  Protein farnesyltransferase (FTase) has recently appeared as a new target of parasitic diseases, a field poor in drugs in development. With the aim of creating new bisubstrate inhibitors of FTase, new farnesyl pyrophosphate analogues have been studied. Farnesyl analogues with a malonic acid function exhibited the best inhibitory activity on FTase. This group was introduced into our imidazole-containing

  蛋白法呢基转移酶（FTase）最近已成为寄生虫病的新靶标，这是一个药物开发领域贫乏的领域。为了产生新的FTase双底物抑制剂，已经研究了新的焦磷酸法呢酯类似物。具有丙二酸功能的法呢基类似物对FTase表现出最好的抑制活性。这一组被引入我们的含咪唑的模型中，从而产生具有亚微摩尔活性的新化合物。已经实现动力学实验以确定它们与酶的结合模式。
• JPS52144616A
  申请人：——

  公开号：JPS52144616A

  公开（公告）日：1977-12-02
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES AUTO-IMMUNS
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015084721A1

  公开（公告）日：2015-06-11

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES NEURO-INFLAMMATOIRES
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015089349A1

  公开（公告）日：2015-06-18

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.